“Patients at risk of Diabetic Ketoacidosis (DKA) during the perioperative time”
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors may place patients at risk of Diabetic Ketoacidosis (DKA) during the perioperative time. We will discuss the position statement Diabetes Australia released in 2020 to assist with the management of this risk.
This presentation discusses how this class of oral hypoglycaemic agents work and the practicalities around their use during the perioperative time.
In this session you will:
- Understand how Sodium-glucose co-transporters-2 (SGLT2) inhibitors work
- Explore the guidelines around their use
- Discuss euglycaemic diabetic ketoacidosis (DKA)
- Investigate the practicalities around ceasing and restarting SGLT2 inhibitors – Practical tips
BPharm, MPS, AACPA, CDE
Donna studied Pharmacy at the University of Queensland and has been a community Pharmacist for over 30 years. She attended further study to become accredited to perform medication reviews with the Australian Consultant Pharmacist Association (AACPA). In her work as a Pharmacist, a significant portion of her clients live with diabetes. This motivated her to study Diabetes education at the Southern Cross University on the Gold Coast and graduate in 2016…Read More>>